Industry
Biotechnology
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Loading...
Open
2.13
Mkt cap
7.8M
Volume
17K
High
2.14
P/E Ratio
-0.72
52-wk high
2.75
Low
2.07
Div yield
N/A
52-wk low
1.55
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 1:07 pm
Portfolio Pulse from Benzinga Newsdesk
May 29, 2024 | 12:49 pm
Portfolio Pulse from Benzinga Newsdesk
May 17, 2024 | 8:09 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 1:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
March 29, 2024 | 3:27 am
Portfolio Pulse from Benzinga Newsdesk
January 08, 2024 | 2:04 pm
Portfolio Pulse from Benzinga Newsdesk
November 09, 2023 | 2:14 pm
Portfolio Pulse from Benzinga Newsdesk
September 19, 2023 | 1:06 pm
Portfolio Pulse from Benzinga Insights
August 30, 2023 | 5:19 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.